Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.

[1]  A. Barrett,et al.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. , 2003, Blood.

[2]  H. Deeg,et al.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. , 2003, Blood.

[3]  A. Dispenzieri,et al.  Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. , 2003, Blood.

[4]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[5]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[6]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[7]  N. Geller,et al.  A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)‐Fc fusion protein in patients with myelodysplastic syndrome , 2002, British journal of haematology.

[8]  T. Okamoto.  [Relationship between response to cyclosporine treatment and HLA-DR in MDS]. , 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[9]  H. Deeg,et al.  Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study , 2002, Leukemia.

[10]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[11]  P. Venugopal,et al.  Correlation of tumor necrosis factor α (TNFα) with high Caspase 3-like activity in myelodysplastic syndromes , 1999 .

[12]  A. Raza,et al.  Tumor Necrosis Factor-α Levels Decrease with Anticytokine Therapy in Patients with Myelodysplastic Syndromes , 1998 .

[13]  P. Kiener,et al.  A role for tumour necrosis factor‐α, Fas and Fas‐Ligand in marrow failure associated with myelodysplastic syndrome , 1998, British journal of haematology.

[14]  A. Barrett,et al.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profiles , 1998, British journal of haematology.

[15]  R. Storb,et al.  Primary Treatment of Acquired Aplastic Anemia: Outcomes with Bone Marrow Transplantation and Immunosuppressive Therapy , 1997, Annals of Internal Medicine.